128 related articles for article (PubMed ID: 37602655)
1. Outcomes for oligometastatic head and neck cancer treated with stereotactic body radiotherapy: Results from an international multi-institutional consortium.
Id Said B; Mutsaers A; Chen H; Husain ZA; Biswas T; Dagan R; Erler D; Foote M; Louie AV; Redmond K; Ricardi U; Sahgal A; Poon I
Head Neck; 2023 Oct; 45(10):2627-2637. PubMed ID: 37602655
[TBL] [Abstract][Full Text] [Related]
2. Metastasis-directed stereotactic body radiation therapy in the management of oligometastatic head and neck cancer.
Franzese C; Badalamenti M; Teriaca A; De Virgilio A; Mercante G; Cavina R; Ferrari D; Santoro A; Spriano G; Scorsetti M
J Cancer Res Clin Oncol; 2021 May; 147(5):1307-1313. PubMed ID: 33471186
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic radiotherapy in the management of oligometastatic and recurrent head and neck cancer: a single-center experience.
Mohamed AA; Goncalves M; Singh BP; Tometten M; Rashad A; Hölzle F; Hackenberg S; Eble M
Strahlenther Onkol; 2024 May; 200(5):400-408. PubMed ID: 38063900
[TBL] [Abstract][Full Text] [Related]
4. An analysis of a large multi-institutional database reveals important associations between treatment parameters and clinical outcomes for stereotactic body radiotherapy (SBRT) of oligometastatic colorectal cancer.
Sheikh S; Chen H; Sahgal A; Poon I; Erler D; Badellino S; Dagan R; Foote MC; Louie AV; Redmond KJ; Ricardi U; Biswas T
Radiother Oncol; 2022 Feb; 167():187-194. PubMed ID: 34952002
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic body radiotherapy for distant metastases to the head and neck.
Mutsaers A; Abugharib A; Poon I; Loblaw J; Bayley A; Zhang L; Chin L; Galapin M; Erler D; Sahgal A; Higgins K; Enepekides D; Eskander A; Karam I
Support Care Cancer; 2024 Mar; 32(4):230. PubMed ID: 38488881
[TBL] [Abstract][Full Text] [Related]
6. Disease course of lung oligometastatic colorectal cancer treated with stereotactic body radiotherapy.
Nicosia L; Cuccia F; Mazzola R; Ricchetti F; Figlia V; Giaj-Levra N; Rigo M; Tomasini D; Pasinetti N; Corradini S; Ruggieri R; Alongi F
Strahlenther Onkol; 2020 Sep; 196(9):813-820. PubMed ID: 32399637
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity.
Franzese C; Bonu ML; Comito T; Clerici E; Loi M; Navarria P; Franceschini D; Pressiani T; Rimassa L; Scorsetti M
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2289-2297. PubMed ID: 32524292
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group "stereotactic radiotherapy".
Rieber J; Streblow J; Uhlmann L; Flentje M; Duma M; Ernst I; Blanck O; Wittig A; Boda-Heggemann J; Krempien R; Lohaus F; Klass ND; Eble MJ; Imhoff D; Kahl H; Petersen C; Gerum S; Henkenberens C; Adebahr S; Hass P; Schrade E; Wendt TG; Hildebrandt G; Andratschke N; Sterzing F; Guckenberger M
Lung Cancer; 2016 Jul; 97():51-8. PubMed ID: 27237028
[TBL] [Abstract][Full Text] [Related]
9. Predictive factors for survival of oligometastatic colorectal cancer treated with Stereotactic body radiation therapy.
Franzese C; Comito T; Toska E; Tozzi A; Clerici E; De Rose F; Franceschini D; Navarria P; Reggiori G; Tomatis S; Scorsetti M
Radiother Oncol; 2019 Apr; 133():220-226. PubMed ID: 30414754
[TBL] [Abstract][Full Text] [Related]
10. Repeat stereotactic body radiotherapy for oligometastatic disease.
Willmann J; Adilovic S; Vlaskou Badra E; Christ SM; Ahmadsei M; Tanadini-Lang S; Mayinger M; Guckenberger M; Andratschke N
Radiother Oncol; 2023 Jul; 184():109671. PubMed ID: 37059336
[TBL] [Abstract][Full Text] [Related]
11. Lung Metastases Treated With Stereotactic Ablative Radiation Therapy in Oligometastatic Colorectal Cancer Patients: Outcomes and Prognostic Factors After Long-Term Follow-Up.
Agolli L; Bracci S; Nicosia L; Valeriani M; De Sanctis V; Osti MF
Clin Colorectal Cancer; 2017 Mar; 16(1):58-64. PubMed ID: 27522627
[TBL] [Abstract][Full Text] [Related]
12. Total tumor volume as a predictor of survival in patients with multiple oligometastases treated with stereotactic ablative radiotherapy (SABR).
Franzese C; Vernier V; Franceschini D; Comito T; Navarria P; Clerici E; Teriaca MA; Massaro M; Di Cristina L; Marini B; Galdieri C; Mancosu P; Tomatis S; Scorsetti M
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10495-10503. PubMed ID: 37280407
[TBL] [Abstract][Full Text] [Related]
13. Late metastatic presentation is associated with improved survival and delayed wide-spread progression after ablative stereotactic body radiotherapy for oligometastasis.
Chen X; Chen H; Poon I; Erler D; Badellino S; Biswas T; Dagan R; Foote M; Louie AV; Ricardi U; Sahgal A; Redmond KJ
Cancer Med; 2021 Sep; 10(18):6189-6198. PubMed ID: 34432390
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the prognostic value of the ESTRO EORTC classification of oligometastatic disease in patients treated with stereotactic body radiotherapy: A retrospective single center study.
Willmann J; Vlaskou Badra E; Adilovic S; Ahmadsei M; Christ SM; van Timmeren JE; Kroeze SGC; Mayinger M; Guckenberger M; Andratschke N
Radiother Oncol; 2022 Mar; 168():256-264. PubMed ID: 35101466
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic body radiotherapy improves the survival of patients with oligometastatic non-small cell lung cancer.
Ouyang W; Yu J; Nuerjiang S; Li Z; Wang D; Wang X; Zhang J; Xie C
Cancer Med; 2019 Aug; 8(10):4605-4614. PubMed ID: 31245933
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of extra-cranial stereotactic body radiotherapy for metastatic colorectal cancer: Dose and site of metastases matter.
Thompson R; Cheung P; Chu W; Myrehaug S; Poon I; Sahgal A; Soliman H; Tseng CL; Wong S; Ung Y; Beatriz Kinupe Abrahão A; Erler D; Zhang L; Ko YJ; Chung HT
Radiother Oncol; 2020 Jan; 142():236-245. PubMed ID: 31543287
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic Body Radiation Therapy (SBRT) Using CyberKnife in Oligometastatic Cancer Patients; Retrospective Evaluation, Single Institution Experience.
Alsuhaibani A; Elashwah A; Alkafi A; Constantinescus C; ALzorkany F
J Gastrointest Cancer; 2019 Dec; 50(4):879-887. PubMed ID: 30291546
[TBL] [Abstract][Full Text] [Related]
18. Patient and Treatment Factors Associated With Improved Local Control and Survival in Oligometastatic Bone Disease: Results From a Large Single-Institution Experience Using Stereotactic Body Radiation Therapy.
Thomas MC; Chen YH; Fite E; Pangilinan A; Bubelo K; Spektor A; Balboni TA; Huynh MA
Int J Radiat Oncol Biol Phys; 2022 Nov; 114(4):747-761. PubMed ID: 35840113
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcome of stereotactic body radiotherapy for lung-only oligometastatic head and neck squamous cell carcinoma: Is the deferral of systemic therapy a potential goal?
Bonomo P; Greto D; Desideri I; Loi M; Di Cataldo V; Orlandi E; Iacovelli NA; Becherini C; Visani L; Salvestrini V; Mariotti M; Livi L
Oral Oncol; 2019 Jun; 93():1-7. PubMed ID: 31109688
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic body radiotherapy for medically unfit patients with cancers to the head and neck.
Al-Assaf H; Erler D; Karam I; Lee JW; Higgins K; Enepekides D; Zhang L; Eskander A; Poon I
Head Neck; 2020 Aug; 42(8):2050-2057. PubMed ID: 32199031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
